BeOne Medicines Ltd. (ONC) is the 15th largest of 300 Pharmaceuticals companies by market capitalisation, at 39.16 Bn, behind Teva Pharmaceutical Industries Ltd at 43.23 Bn. It trades on a P/E of 58.96, 218% above the peer median of 18.56. The table below compares all 300 on 8 financial metrics.
| # | Ticker | Company | match | industry_code | industry_group | industry_group_code | Market Capitalization | P/E | P/S | Enterprise Value |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JNJ | Johnson & Johnson | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 640.12 Bn | 30.40 | 6.54 | 619.36 Bn |
| 2 | ABBV | AbbVie Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 454.24 Bn | 72.00 | 7.05 | 447.72 Bn |
| 3 | MRK | Merck & Co., Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 355.10 Bn | 112.18 | 5.33 | 348.01 Bn |
| 4 | NVS | Novartis Ag | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 261.78 Bn | 9.24 | 3.81 | 254.49 Bn |
| 5 | PFE | Pfizer Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 157.82 Bn | 36.13 | 2.48 | 146.43 Bn |
| 6 | SNY | Sanofi | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 52.15 Bn | 11.20 | 0.97 | 45.19 Bn |
| 7 | RVMD | Revolution Medicines, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 43.66 Bn | -24.30 | — | 43.66 Bn |
| 8 | ONC | BeOne Medicines Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 39.16 Bn | 58.96 | 6.39 | 34.07 Bn |
| 9 | INCY | Incyte Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 24.41 Bn | 15.10 | 4.19 | 19.88 Bn |
| 10 | UTHR | UNITED THERAPEUTICS Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 21.22 Bn | 16.15 | 6.73 | 18.55 Bn |
| 11 | JAZZ | Jazz Pharmaceuticals plc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.96 Bn | 16.51 | 3.47 | 14.34 Bn |
| 12 | NBIX | Neurocrine Biosciences Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 15.87 Bn | 22.36 | 4.70 | 15.48 Bn |
| 13 | EXEL | Exelixis, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 13.97 Bn | 16.35 | 5.73 | 13.13 Bn |
| 14 | CORT | Corcept Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 12.19 Bn | 219.28 | 14.68 | 11.88 Bn |
| 15 | AXSM | Axsome Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 11.55 Bn | -74.38 | 14.87 | 11.23 Bn |
| 16 | CYTK | Cytokinetics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 10.26 Bn | -13.28 | 151.56 | 9.09 Bn |
| 17 | NUVL | Nuvalent, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.75 Bn | -27.07 | — | 9.75 Bn |
| 18 | KYMR | Kymera Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 9.52 Bn | -37.67 | 90.64 | 8.83 Bn |
| 19 | CRNX | Crinetics Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.99 Bn | -17.90 | 213.22 | 8.99 Bn |
| 20 | GPCR | Structure Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 8.26 Bn | -44.78 | — | 8.26 Bn |
| 21 | ALKS | Alkermes plc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 7.70 Bn | 116.10 | 4.62 | 7.05 Bn |
| 22 | BLTE | Belite Bio, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.84 Bn | 0.08 | — | 6.84 Bn |
| 23 | TVTX | Travere Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 6.23 Bn | -142.31 | 10.54 | 6.11 Bn |
| 24 | LQDA | Liquidia Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 5.95 Bn | 42.81 | 13.19 | 5.66 Bn |
| 25 | AMRN | Amarin Corp Plc\Uk | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 5.80 Bn | -211.88 | 31.13 | 5.48 Bn |
| 26 | ACAD | Acadia Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.79 Bn | 12.55 | 4.21 | 3.83 Bn |
| 27 | EWTX | Edgewise Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.79 Bn | -24.24 | — | 4.79 Bn |
| 28 | DFTX | Definium Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.30 Bn | -12.17 | — | 4.30 Bn |
| 29 | MANE | Veradermics, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.14 Bn | -46.53 | — | 4.14 Bn |
| 30 | INDV | Indivior Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 4.07 Bn | 11.56 | 3.06 | 3.85 Bn |
| 31 | ELVN | Enliven Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.98 Bn | -42.72 | — | 3.98 Bn |
| 32 | CPRX | CATALYST PHARMACEUTICALS, INC. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.85 Bn | 17.94 | 6.45 | 3.09 Bn |
| 33 | OGN | Organon & Co. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.58 Bn | 17.14 | 0.58 | 2.45 Bn |
| 34 | GOSS | Gossamer Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.43 Bn | -20.05 | 64.44 | 3.38 Bn |
| 35 | TARS | Tarsus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 3.43 Bn | -73.33 | 5.66 | 2.98 Bn |
| 36 | NAMS | NewAmsterdam Pharma Co N.V. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.68 Bn | -10.84 | 376.70 | 2.68 Bn |
| 37 | TAK | Takeda Pharmaceutical Co Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.64 Bn | 4.56 | 0.06 | -3.15 Bn |
| 38 | MLYS | Mineralys Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.49 Bn | -6.83 | — | 2.49 Bn |
| 39 | SUPN | Supernus Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | -28.41 | 3.07 | 2.05 Bn |
| 40 | HRMY | Harmony Biosciences Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | 13.48 | 2.51 | 1.61 Bn |
| 41 | TRVI | Trevi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.26 Bn | -59.03 | — | 2.26 Bn |
| 42 | PVLA | Palvella Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -40.67 | — | 1.85 Bn |
| 43 | AUPH | Aurinia Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.14 Bn | 6.67 | 6.87 | 1.70 Bn |
| 44 | NUVB | Nuvation Bio Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 2.10 Bn | -19.58 | 12.38 | 2.10 Bn |
| 45 | ETON | Eton Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | 165.23 | 16.11 | 1.59 Bn |
| 46 | INVA | Innoviva, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | 7.73 | 2.91 | 0.92 Bn |
| 47 | XERS | Xeris Biopharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.29 Bn | -75.01 | 3.86 | 1.17 Bn |
| 48 | HROW | Harrow, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.29 Bn | -38.49 | 4.69 | 1.21 Bn |
| 49 | LBRX | Lb Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.28 Bn | -22.23 | — | 1.28 Bn |
| 50 | OPK | Opko Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.17 Bn | -31.30 | 1.99 | 0.87 Bn |
| 51 | KURA | Kura Oncology, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | -4.25 | 13.12 | 1.01 Bn |
| 52 | PCRX | Pacira BioSciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 1.01 Bn | 68.37 | 1.35 | 0.76 Bn |
| 53 | SGP | SpyGlass Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.92 Bn | -46.33 | — | 0.92 Bn |
| 54 | DSGN | Design Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.92 Bn | -11.31 | — | 0.71 Bn |
| 55 | OLMA | Olema Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | -5.23 | — | 0.89 Bn |
| 56 | LXRX | Lexicon Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.89 Bn | -13.92 | 21.55 | 0.70 Bn |
| 57 | IVA | Inventiva S.A. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.78 Bn | 8.05 | 148.86 | 0.78 Bn |
| 58 | COLL | Collegium Pharmaceutical, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.74 Bn | 15.41 | 0.91 | 0.59 Bn |
| 59 | GYRE | Gyre Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.71 Bn | -36.68 | 5.98 | 0.69 Bn |
| 60 | ZVRA | Zevra Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.71 Bn | 12.19 | 5.23 | 0.49 Bn |
| 61 | PHAT | Phathom Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.67 Bn | -7.13 | 2.79 | 0.48 Bn |
| 62 | VSTM | Verastem, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.66 Bn | -6.36 | 7.57 | 0.53 Bn |
| 63 | NVCT | Nuvectis Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.64 Bn | -18.60 | — | 0.64 Bn |
| 64 | CRMD | CorMedix Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.61 Bn | 4.87 | 1.62 | 0.35 Bn |
| 65 | AQST | Aquestive Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.60 Bn | -7.64 | 11.09 | 0.50 Bn |
| 66 | MPLT | MapLight Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.59 Bn | -2.92 | — | 0.59 Bn |
| 67 | EOLS | Evolus, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.52 Bn | -15.06 | 1.64 | 0.47 Bn |
| 68 | OVID | Ovid Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.50 Bn | -15.40 | 313.96 | 0.38 Bn |
| 69 | SPRY | ARS Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.47 Bn | -2.14 | 4.05 | 0.33 Bn |
| 70 | XFOR | X4 Pharmaceuticals, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.44 Bn | -4.91 | 27.90 | 0.25 Bn |
| 71 | IKT | Inhibikase Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.41 Bn | -6.24 | — | 0.36 Bn |
| 72 | VTVT | vTv Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.40 Bn | -83.42 | 10.77 | 0.40 Bn |
| 73 | TTRX | Turn Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.38 Bn | -49.09 | — | 0.38 Bn |
| 74 | PALI | Palisade Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.36 Bn | -12.34 | 715.21 | 0.23 Bn |
| 75 | SION | Sionna Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.35 Bn | -3.64 | — | 0.35 Bn |
| 76 | EBS | Emergent BioSolutions Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.32 Bn | -1.82 | 0.41 | 0.18 Bn |
| 77 | ACHV | Achieve Life Sciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | — | — | 0.31 Bn |
| 78 | VNDA | Vanda Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.31 Bn | -1.12 | 1.43 | 0.14 Bn |
| 79 | FULC | Fulcrum Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.29 Bn | -3.26 | — | 0.29 Bn |
| 80 | IMRX | Immuneering Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.28 Bn | -4.70 | — | 0.28 Bn |
| 81 | AKBA | Akebia Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.26 Bn | -8.63 | 1.18 | 0.10 Bn |
| 82 | ZNTL | Zentalis Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.25 Bn | -1.79 | — | 0.25 Bn |
| 83 | SIGA | Siga Technologies Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.22 Bn | — | — | 0.06 Bn |
| 84 | CELG-RI | Bristol Myers Squibb Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | 0.02 | 0.00 | -10.86 Bn |
| 85 | CRDL | Cardiol Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -6.69 | — | 0.20 Bn |
| 86 | TNXP | Tonix Pharmaceuticals Holding Corp. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -1.24 | 6.85 | 0.20 Bn |
| 87 | DERM | Journey Medical Corp | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -54.37 | 2.92 | 0.17 Bn |
| 88 | NERV | Minerva Neurosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.20 Bn | -29.44 | — | 0.20 Bn |
| 89 | MCUJF | Medicure Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -38.28 | 8.36 | 0.19 Bn |
| 90 | ACOG | Alpha Cognition Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.19 Bn | -7.06 | 14.48 | 0.15 Bn |
| 91 | SLGL | Sol-Gel Technologies Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.18 Bn | -17.52 | 102.35 | 0.14 Bn |
| 92 | LONA | LeonaBio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.16 Bn | -1.34 | — | 0.11 Bn |
| 93 | MENS | Jyong Biotech Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.15 Bn | -38.88 | — | 0.15 Bn |
| 94 | LENZ | LENZ Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.14 Bn | -1.10 | 6.61 | 0.14 Bn |
| 95 | BMEA | Biomea Fusion, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.13 Bn | -2.23 | — | 0.13 Bn |
| 96 | VANI | Vivani Medical, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -4.06 | — | 0.09 Bn |
| 97 | AARD | Aardvark Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.11 Bn | -1.60 | — | 0.04 Bn |
| 98 | CPIX | Cumberland Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -8.88 | 3.06 | 0.09 Bn |
| 99 | NTHI | Neonc Technologies Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.10 Bn | -2.04 | — | 0.10 Bn |
| 100 | CGTX | Cognition Therapeutics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -2.43 | — | 0.09 Bn |
| 101 | MNOV | Medicinova Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.09 Bn | -7.80 | 102.63 | 0.09 Bn |
| 102 | VRCA | Verrica Pharmaceuticals Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -3.33 | 2.78 | 0.07 Bn |
| 103 | TENX | Tenax Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -1.30 | — | 0.08 Bn |
| 104 | PTHS | Pelthos Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.08 Bn | -0.68 | 1.48 | 0.06 Bn |
| 105 | PMVP | PMV Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -1.23 | — | 0.00 Bn |
| 106 | RGC | Regencell Bioscience Holdings Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | — | — | 0.07 Bn |
| 107 | PLRX | Pliant Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -0.78 | — | 0.07 Bn |
| 108 | CING | Cingulate Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.07 Bn | -3.06 | — | 0.07 Bn |
| 109 | BOLD | Boundless Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | -0.99 | — | 0.06 Bn |
| 110 | VERU | Veru Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.06 Bn | 112.31 | — | 0.03 Bn |
| 111 | ANVS | Annovis Bio, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.86 | — | 0.05 Bn |
| 112 | KPTI | Karyopharm Therapeutics Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -0.23 | 0.31 | -0.02 Bn |
| 113 | CLNN | Clene Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.05 Bn | -1.33 | 218.27 | 0.05 Bn |
| 114 | IXHL | Incannex Healthcare Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.83 | — | 0.04 Bn |
| 115 | APRE | Aprea Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -3.31 | — | 0.04 Bn |
| 116 | GRCE | Grace Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -1.92 | — | 0.04 Bn |
| 117 | SCLX | Scilex Holding Co | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.04 Bn | -0.08 | 1.11 | -0.08 Bn |
| 118 | UG | United Guardian Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | 14.56 | 2.94 | 0.02 Bn |
| 119 | BYSI | BeyondSpring Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -3.70 | — | 0.03 Bn |
| 120 | CPHI | China Pharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -6.97 | 7.97 | 0.03 Bn |
| 121 | NSRX | Nasus Pharma Ltd | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -5.64 | — | 0.03 Bn |
| 122 | CRVO | CervoMed Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.87 | 79.47 | 0.03 Bn |
| 123 | ACTU | Actuate Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -1.23 | — | 0.03 Bn |
| 124 | ATOS | Atossa Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.03 Bn | -0.74 | — | 0.03 Bn |
| 125 | TXMD | TherapeuticsMD, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -135.13 | 7.65 | 0.02 Bn |
| 126 | YARW | Yarrow Bioscience, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.11 | 46.16 | 0.00 Bn |
| 127 | BFRI | Biofrontera Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.26 | 0.49 | 0.02 Bn |
| 128 | AYTU | Aytu Biopharma, Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.68 | 0.38 | -0.01 Bn |
| 129 | ALLR | Allarity Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.60 | 776.44 | 0.02 Bn |
| 130 | MIRA | Mira Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.55 | — | 0.01 Bn |
| 131 | TVRD | Tvardi Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.67 | — | 0.02 Bn |
| 132 | KPRX | Kiora Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -1.49 | — | 0.02 Bn |
| 133 | CTXR | Citius Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -0.33 | 2.24 | 0.03 Bn |
| 134 | INTI | Inhibitor Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.02 Bn | -4.72 | — | 0.02 Bn |
| 135 | ANEB | Anebulo Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.51 | — | 0.01 Bn |
| 136 | CALC | CalciMedica, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.32 | -8.02 | -0.01 Bn |
| 137 | ACXP | Acurx Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.79 | — | 0.01 Bn |
| 138 | CURX | Curanex Pharmaceuticals Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.85 | — | 0.00 Bn |
| 139 | RVPH | Reviva Pharmaceuticals Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.71 | — | 0.01 Bn |
| 140 | PCSA | Processa Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.43 | — | 0.01 Bn |
| 141 | TRAW | Traws Pharma, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -0.36 | — | 0.00 Bn |
| 142 | PULM | Pulmatrix, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.01 Bn | -1.27 | — | 0.01 Bn |
| 143 | BICX | BioCorRx Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.64 | 6.70 | 0.00 Bn |
| 144 | TCRT | Alaunos Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.90 | 1,251.36 | 0.00 Bn |
| 145 | CVKD | Cadrenal Therapeutics, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.27 | — | 0.00 Bn |
| 146 | ADXN | Addex Therapeutics Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.04 | — | 0.00 Bn |
| 147 | CASIF | CASI Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.02 | 0.12 | 0.00 Bn |
| 148 | OGEN | Oragenics Inc | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.21 | — | 0.00 Bn |
| 149 | UPC | Universe Pharmaceuticals INC | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | -1,490.23 Bn |
| 150 | CANF | Can-Fite BioPharma Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.24 | 5.93 | 0.00 Bn |
| 151 | ENSC | Ensysce Biosciences, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 152 | MTNB | Matinas BioPharma Holdings, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.17 | — | 0.00 Bn |
| 153 | SKVI | Skinvisible, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -1.05 | 54.04 | 0.00 Bn |
| 154 | JAGX | Jaguar Health, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | 0.03 | -0.01 Bn |
| 155 | SPRC | SciSparc Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.05 | 0.74 | 0.00 Bn |
| 156 | NCEL | NewcelX Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -0.06 | — | 0.00 Bn |
| 157 | GLMD | Galmed Pharmaceuticals Ltd. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | — | — | 0.00 Bn |
| 158 | GCAN | Trafalgar International, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | -2.85 | — | 0.00 Bn |
| 159 | CDT | CDT Equity Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 160 | SXTC | China SXT Pharmaceuticals, Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | 0.03 | -0.03 Bn |
| 161 | CMND | Clearmind Medicine Inc. | primary | H-01 | Pharmaceuticals and Biotechnology | HG-01 | 0.00 Bn | 0.00 | — | 0.00 Bn |
| 162 | AMGN | Amgen Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 204.00 Bn | 23.31 | 5.35 | 190.01 Bn |
| 163 | GILD | Gilead Sciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 178.36 Bn | -61.71 | 5.86 | 175.09 Bn |
| 164 | VRTX | Vertex Pharmaceuticals Inc / Ma | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 130.59 Bn | 29.68 | 10.37 | 122.73 Bn |
| 165 | REGN | Regeneron Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 80.34 Bn | 18.56 | 5.17 | 72.34 Bn |
| 166 | ARGX | Argenx Se | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 60.92 Bn | 35.18 | 11.66 | 55.73 Bn |
| 167 | MRNA | Moderna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 57.44 Bn | -18.18 | 25.78 | 52.31 Bn |
| 168 | TEVA | Teva Pharmaceutical Industries Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 43.23 Bn | 62.10 | 2.50 | 39.58 Bn |
| 169 | ALNY | Alnylam Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 33.26 Bn | 42.89 | 6.92 | 29.95 Bn |
| 170 | ALC | Alcon Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 32.18 Bn | 50.65 | 2.99 | 30.73 Bn |
| 171 | BIIB | Biogen Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 32.08 Bn | 38.43 | 3.20 | 30.80 Bn |
| 172 | ROIV | Roivant Sciences Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 29.50 Bn | -19.82 | 2,700.66 | 30.19 Bn |
| 173 | GEHC | GE HealthCare Technologies Inc. | secondary | H-08 | Medical Devices and Diagnostics | HG-02 | 28.88 Bn | 14.12 | 1.36 | 27.00 Bn |
| 174 | INSM | INSMED Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 28.25 Bn | -32.13 | 24.83 | 27.09 Bn |
| 175 | BNTX | BioNTech SE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 24.46 Bn | -13.72 | 7.91 | 10.81 Bn |
| 176 | VTRS | Viatris Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 18.96 Bn | -46.76 | 1.29 | 18.08 Bn |
| 177 | ZBH | Zimmer Biomet Holdings, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 17.83 Bn | 21.20 | 2.10 | 17.43 Bn |
| 178 | ASND | Ascendis Pharma A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 16.33 Bn | 18.42 | 11.52 | 15.39 Bn |
| 179 | MDGL | Madrigal Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 15.58 Bn | -48.83 | 12.13 | 14.74 Bn |
| 180 | BBIO | BridgeBio Pharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 14.15 Bn | -20.50 | 19.84 | 13.44 Bn |
| 181 | SMMT | Summit Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 13.92 Bn | — | — | 13.23 Bn |
| 182 | BWXT | BWX Technologies, Inc. | secondary | I-39 | Clean Energy Equipment | IG-10 | 13.76 Bn | 38.67 | 3.91 | 13.15 Bn |
| 183 | BMRN | Biomarin Pharmaceutical Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.71 Bn | 174.09 | 3.73 | 11.84 Bn |
| 184 | HALO | Halozyme Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 12.23 Bn | 30.40 | 7.35 | 11.99 Bn |
| 185 | KNSA | Kiniksa Pharmaceuticals International, plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.90 Bn | 73.36 | 14.15 | 11.37 Bn |
| 186 | ARWR | Arrowhead Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 11.69 Bn | -43.65 | 17.47 | 10.09 Bn |
| 187 | APGE | Apogee Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 10.18 Bn | -34.62 | — | 9.20 Bn |
| 188 | GMED | Globus Medical Inc | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 9.96 Bn | 18.71 | 3.17 | 9.37 Bn |
| 189 | RDY | Dr Reddys Laboratories Ltd | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 9.92 Bn | 784.47 | 2.71 | 9.79 Bn |
| 190 | GKOS | GLAUKOS Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 9.85 Bn | -62.49 | 16.07 | 9.74 Bn |
| 191 | PTGX | Protagonist Therapeutics, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.58 Bn | 88.48 | 33.98 | 9.58 Bn |
| 192 | PRAX | Praxis Precision Medicines, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.34 Bn | -25.56 | — | 8.58 Bn |
| 193 | ABVX | Abivax S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 9.32 Bn | -22.17 | — | 9.32 Bn |
| 194 | IONS | Ionis Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.98 Bn | -42.25 | 10.27 | 6.92 Bn |
| 195 | PCVX | Vaxcyte, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.61 Bn | -8.13 | — | 8.61 Bn |
| 196 | IBRX | ImmunityBio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.33 Bn | -8.37 | 50.25 | 7.97 Bn |
| 197 | TGTX | Tg Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 8.25 Bn | 17.29 | 10.32 | 7.57 Bn |
| 198 | SYRE | Spyre Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.98 Bn | -42.91 | — | 7.98 Bn |
| 199 | IMVT | Immunovant, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.71 Bn | -14.27 | — | 7.71 Bn |
| 200 | RYTM | Rhythm Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 7.21 Bn | -34.17 | 30.03 | 6.87 Bn |
| 201 | SRRK | Scholar Rock Holding Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.74 Bn | -17.92 | — | 6.74 Bn |
| 202 | BLRX | BioLineRx Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.55 Bn | -690.92 | 4,707.72 | 6.56 Bn |
| 203 | CGON | CG Oncology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.39 Bn | -28.47 | 1,025.85 | 6.39 Bn |
| 204 | MIRM | Mirum Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 6.36 Bn | -7.24 | 10.29 | 5.92 Bn |
| 205 | BLCO | Bausch & Lomb Corp | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 6.16 Bn | -37.79 | 1.16 | 5.85 Bn |
| 206 | ORKA | Oruka Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.81 Bn | — | — | 4.08 Bn |
| 207 | COGT | Cogent Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.73 Bn | -15.46 | — | 5.73 Bn |
| 208 | XENE | Xenon Pharmaceuticals Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.67 Bn | -16.11 | — | 5.67 Bn |
| 209 | LGND | Ligand Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.67 Bn | 28.94 | 19.50 | 4.31 Bn |
| 210 | PTCT | Ptc Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.50 Bn | 14.34 | 5.46 | 3.28 Bn |
| 211 | AMRX | Amneal Pharmaceuticals, Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 5.43 Bn | 25.22 | 1.74 | 5.39 Bn |
| 212 | GRFS | Grifols SA | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.14 Bn | 20.24 | 0.31 | 6.69 Bn |
| 213 | DBVT | DBV Technologies S.A. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 5.14 Bn | -29.19 | 1,023.59 | 4.96 Bn |
| 214 | ERAS | Erasca, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.96 Bn | -17.22 | — | 4.96 Bn |
| 215 | RADX | Radiopharm Theranostics Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.68 Bn | -55.95 | 19,321.15 | 4.68 Bn |
| 216 | DNTH | Dianthus Therapeutics, Inc. /DE/ | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.55 Bn | — | — | 4.15 Bn |
| 217 | RLAY | Relay Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.12 Bn | -13.39 | 398.42 | 4.12 Bn |
| 218 | CELC | Celcuity Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.08 Bn | -20.90 | — | 4.08 Bn |
| 219 | TNGX | Tango Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 4.00 Bn | -34.83 | 74.41 | 2.99 Bn |
| 220 | IOVA | Iovance Biotherapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 3.90 Bn | -18.52 | 11.99 | 3.60 Bn |
| 221 | TLX | Telix Pharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.82 Bn | — | — | 3.53 Bn |
| 222 | VKTX | Viking Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.73 Bn | -6.95 | — | 3.73 Bn |
| 223 | IDYA | IDEAYA Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.62 Bn | -15.72 | 15.47 | 2.79 Bn |
| 224 | AMLX | Amylyx Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.52 Bn | -28.93 | — | 3.52 Bn |
| 225 | DNLI | Denali Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.37 Bn | -7.73 | 934.86 | 3.37 Bn |
| 226 | ABCL | AbCellera Biologics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.34 Bn | -20.21 | 50.44 | 3.34 Bn |
| 227 | RCUS | Arcus Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.12 Bn | -6.74 | 26.67 | 2.42 Bn |
| 228 | DYN | Dyne Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.02 Bn | -5.83 | — | 3.02 Bn |
| 229 | ARQT | Arcutis Biotherapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 3.00 Bn | 109.45 | 6.47 | 2.76 Bn |
| 230 | CLDX | Celldex Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.90 Bn | -9.34 | 18,333.27 | 2.90 Bn |
| 231 | MBX | MBX Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.83 Bn | -26.99 | — | 2.83 Bn |
| 232 | IMNM | Immunome Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.80 Bn | -10.33 | 593.06 | 2.28 Bn |
| 233 | ATAI | AtaiBeckley Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.71 Bn | -22.77 | 550.23 | 2.71 Bn |
| 234 | ZLAB | Zai Lab Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.71 Bn | -14.33 | 6.03 | 2.00 Bn |
| 235 | IRON | Disc Medicine, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.69 Bn | -13.46 | — | 2.69 Bn |
| 236 | NRIX | Nurix Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.60 Bn | -8.17 | 70.80 | 2.16 Bn |
| 237 | CURLF | Curaleaf Holdings, Inc. | secondary | S-09 | Tobacco and Cannabis | SG-04 | 2.55 Bn | -21.40 | 1.95 | 2.46 Bn |
| 238 | VERA | Vera Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.53 Bn | -6.29 | — | 2.53 Bn |
| 239 | PHVS | Pharvaris N.V. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.48 Bn | -11.33 | — | 2.11 Bn |
| 240 | XTLB | Xtl Biopharmaceuticals Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.42 Bn | -3,022.64 | — | 2.42 Bn |
| 241 | VRDN | Viridian Therapeutics, Inc.\DE | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.41 Bn | -5.58 | 33.82 | 2.41 Bn |
| 242 | SLS | SELLAS Life Sciences Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.33 Bn | -67.31 | — | 2.33 Bn |
| 243 | NKTR | Nektar Therapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.31 Bn | -19.40 | 42.24 | 1.62 Bn |
| 244 | OCUL | Ocular Therapeutix, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.30 Bn | -7.79 | 44.25 | 2.30 Bn |
| 245 | AXGN | Axogen, Inc. | secondary | H-06 | Medical Devices and Diagnostics | HG-02 | 2.26 Bn | -152.02 | 9.01 | 2.15 Bn |
| 246 | HCM | HUTCHMED (China) Ltd | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.24 Bn | 0.01 | 3.41 | 2.25 Bn |
| 247 | BHC | Bausch Health Companies Inc. | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 2.19 Bn | -2.01 | 0.20 | 1.32 Bn |
| 248 | SRPT | Sarepta Therapeutics, Inc. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 2.16 Bn | -15.73 | 1.09 | 1.37 Bn |
| 249 | RAPP | Rapport Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | -15.10 | 104.59 | 2.09 Bn |
| 250 | GMAB | Genmab A/S | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.09 Bn | 0.17 | 0.33 | 0.58 Bn |
| 251 | ADMA | Adma Biologics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.08 Bn | 12.67 | 4.06 | 1.94 Bn |
| 252 | FMS | Fresenius Medical Care AG | secondary | H-14 | Healthcare Providers | HG-04 | 2.08 Bn | 1.98 | 0.07 | 1.38 Bn |
| 253 | BCRX | Biocryst Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -5.37 | 3.88 | 1.72 Bn |
| 254 | URGN | UroGen Pharma Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -34.23 | 10.96 | 1.96 Bn |
| 255 | KOD | Kodiak Sciences Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.07 Bn | -8.52 | — | 2.07 Bn |
| 256 | AGIO | Agios Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 2.00 Bn | -4.86 | 20.37 | 2.00 Bn |
| 257 | ZBIO | Zenas BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.97 Bn | -4.72 | 1,970.85 | 1.97 Bn |
| 258 | CMPS | COMPASS Pathways plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.95 Bn | -4.92 | — | 1.95 Bn |
| 259 | BHVN | Biohaven Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.92 Bn | -3.27 | — | 1.65 Bn |
| 260 | ZYME | Zymeworks Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.87 Bn | -12.77 | 50.47 | 1.60 Bn |
| 261 | XNCR | Xencor Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.81 Bn | -11.34 | 17.28 | 1.44 Bn |
| 262 | STOK | Stoke Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.81 Bn | -9.22 | 65.66 | 1.52 Bn |
| 263 | VIR | Vir Biotechnology, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.80 Bn | -7.08 | 5.92 | 1.80 Bn |
| 264 | LKFT | Lakefront Biotherapeutics NV | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.77 Bn | 0.00 | 1.53 | 1.77 Bn |
| 265 | SEPN | Septerna, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.76 Bn | -124.23 | 17.79 | 1.76 Bn |
| 266 | DMRA | Damora Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.73 Bn | -6.54 | — | 1.19 Bn |
| 267 | RXRX | Recursion Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.71 Bn | -3.28 | 31.16 | 1.16 Bn |
| 268 | GHRS | GH Research PLC | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.69 Bn | -26.66 | — | 1.32 Bn |
| 269 | IMCR | Immunocore Holdings plc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.68 Bn | -91.81 | 3.90 | 0.80 Bn |
| 270 | ANIP | Ani Pharmaceuticals Inc | secondary | H-04 | Pharmaceuticals and Biotechnology | HG-01 | 1.67 Bn | 13.76 | 1.71 | 1.31 Bn |
| 271 | SNDX | Syndax Pharmaceuticals Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.62 Bn | -8.93 | 6.43 | 1.07 Bn |
| 272 | INBX | Inhibrx Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.61 Bn | -12.84 | 1,236.34 | 1.61 Bn |
| 273 | FBRX | Forte Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.58 Bn | -20.71 | — | 1.23 Bn |
| 274 | ANAB | Anaptysbio, Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.56 Bn | -64.72 | 7.85 | 1.28 Bn |
| 275 | NVAX | Novavax Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | -6.26 | 3.75 | 0.83 Bn |
| 276 | SCNI | Scinai Immunotherapeutics Ltd. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.55 Bn | -185.09 | 900.32 | 1.55 Bn |
| 277 | BCAX | Bicara Therapeutics Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -8.36 | — | 1.50 Bn |
| 278 | AAPG | Ascentage Pharma Group International | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.50 Bn | -9.11 | 20.12 | 1.22 Bn |
| 279 | RARE | Ultragenyx Pharmaceutical Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -3.15 | 1.97 | 1.12 Bn |
| 280 | ABSI | Absci Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.41 Bn | -10.68 | 902.60 | 1.21 Bn |
| 281 | AVBP | ArriVent BioPharma, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.40 Bn | -8.43 | — | 1.40 Bn |
| 282 | MAZE | Maze Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.37 Bn | -13.68 | 68.27 | 1.37 Bn |
| 283 | CGEM | Cullinan Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.32 Bn | -6.24 | — | 1.32 Bn |
| 284 | OMER | Omeros Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.32 Bn | 77.25 | 34.30 | 1.32 Bn |
| 285 | TYRA | Tyra Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.31 Bn | -9.79 | — | 1.31 Bn |
| 286 | SDGR | Schrodinger, Inc. | secondary | T-27 | Vertical Software | TG-05 | 1.25 Bn | -26.15 | 4.82 | 0.83 Bn |
| 287 | ORIC | Oric Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.25 Bn | -8.27 | — | 1.25 Bn |
| 288 | VOR | Vor Biopharma Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.21 Bn | -1.32 | — | 1.21 Bn |
| 289 | GLUE | Monte Rosa Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.20 Bn | -9.27 | 41.74 | 0.57 Bn |
| 290 | IMTX | Immatics N.V. | secondary | H-03 | Pharmaceuticals and Biotechnology | HG-01 | 1.18 Bn | -4.46 | 24.25 | 0.72 Bn |
| 291 | MNKD | Mannkind Corp | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.16 Bn | -26.58 | 2.95 | 1.05 Bn |
| 292 | ALMS | Alumis Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.14 Bn | -4.84 | 137.26 | 0.64 Bn |
| 293 | JBIO | Jade Biosciences, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.14 Bn | -7.13 | — | 1.14 Bn |
| 294 | ANRO | Alto Neuroscience, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.12 Bn | -16.36 | — | 1.12 Bn |
| 295 | SVRA | Savara Inc | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.09 Bn | -9.65 | — | 1.09 Bn |
| 296 | CRVS | Corvus Pharmaceuticals, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.09 Bn | -24.95 | — | 0.87 Bn |
| 297 | CLYM | Climb Bio, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.09 Bn | -18.86 | — | 1.09 Bn |
| 298 | REPL | Replimune Group, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.09 Bn | -4.21 | — | 1.09 Bn |
| 299 | MLTX | MoonLake Immunotherapeutics | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.06 Bn | -3.49 | — | 0.53 Bn |
| 300 | JANX | Janux Therapeutics, Inc. | secondary | H-02 | Pharmaceuticals and Biotechnology | HG-01 | 1.04 Bn | -10.49 | 43.52 | 1.04 Bn |